Log in Free sign up

Cellectis (CLLS) News and press releases

News

From Benzinga Pro

Goldman Sachs Maintains Sell on Cellectis, Lowers Price Target to $2

News, Price Target, Analyst Ratings

Goldman Sachs maintains Cellectis (NASDAQ:CLLS) with a Sell and lowers the price target from $3 to $2.

71 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.

38 Stocks Moving In Thursday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Baird Upgrades Cellectis to Outperform

News, Upgrades, Analyst Ratings

Baird analyst Jack Allen upgrades Cellectis (NASDAQ:CLLS) from Neutral to Outperform.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Pre-Market Outlook, Markets, Movers

Barclays Maintains Overweight on Cellectis, Lowers Price Target to $7

News, Price Target, Analyst Ratings

Barclays analyst Gena Wang maintains Cellectis (NASDAQ:CLLS) with a Overweight and lowers the price target from $9 to $7.

Cellectis Q1 EPS $(0.64) Down From $(0.26) YoY, Sales $3.83M Down From $27.97M YoY

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.64) per share. This is a 146.15 percent decrease over losses of $(0.26) per share from the same period last year. The company reported $3.83 million in sales this

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 1043 companies hit new 52-week lows.

Natural Killer Cell Therapy Focused-Cytovia Turns To SPAC Merger For Public Market Debut

Biotech, News, Penny Stocks, Health Care, Financing, Offerings, IPOs, General

Cellectis Reveals Preclinical Data On First Allogeneic Dual CAR T-Cell Product In Non-Hodgkin Lymphoma

Biotech, News, Penny Stocks, Health Care, General

Cellectis To Present Preclinical Data On UCART20x22 At AACR Apr. 10

Biotech, News, Events, General

Preclinical data demonstrated POC with robust in vitro and in vivo anti-tumor activity UCART20x22 allogeneic dual CAR T has been designed and engineered on the TRAC / CD52

Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers

Biotech, News, Penny Stocks, Health Care, Small Cap, General

Iovance Biotherapeutics Reports Its Investigational New Drug Application Allowed To Proceed For TALEN-Edited Tumor Infiltrating Lymphocyte

Biotech, News, FDA, General

Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001 to Deliver TIL and PD-1 Inhibition within a Single Cancer Therapy First Genetically Modified Iovance TIL Therapy Leverages

Cathie Wood's Ark Sits Out Thursday's Dip In Favorite Stocks

Cryptocurrency, News, Penny Stocks, Sector ETFs, Broad U.S. Equity ETFs, Short Ideas, Small Cap, Markets, Tech, Trading Ideas, ETFs

Popular stock picker Cathie Wood's Ark Investment Management on Thursday stayed away from buying more shares in favorite stocks on the dip. The St. Petersburg, Florida-based Ark Invest’s daily data revealed a total of seven trades and none of them were among the top constituents in any of its actively-traded exchange funds.

Stocks That Hit 52-Week Lows On Monday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Monday, 524 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 368 stocks hit new 52-week lows.

Recap: Cellectis Q4 Earnings

Cellectis (NASDAQ:CLLS) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cellectis beat estimated earnings by 47.83%, reporting an EPS of $-0.48 versus an estimate of $-0.92.

UPDATE: Cellectis Q4 Adj. EPS $(0.48) Beats $(0.92) Estimate

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.92) by 47.83 percent. This is a 45.45 percent increase over losses of $(0.88) per share from the

Cellectis Q4 EPS $(0.55) Beats $(0.92) Estimate, Sales $13.66M Beat $8.72M Estimate

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.92) by 40.22 percent. This is a 37.5 percent increase over losses of $(0.88) per share from the same

Press releases

From Benzinga Pro

Cellectis' Annual Shareholders' General Meeting to be Held on June 28, 2022

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Cellectis ((Euronext Growth: ALCLS, NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene

Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT

NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022

Earnings, Press Releases

◦ UCART20x22 preclinical data presented at AACR demonstrated PoC with robust in vitro and in vivo anti-tumor activity ◦ Published two articles in Nature Communications providing preclinical validation for the

Cellectis to Report First Quarter 2022 Financial Results

News, Press Releases

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,

Calyxt, Inc., Cellectis' Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results

Earnings, Press Releases

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today

Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics

News, Financing, Press Releases

Cellectis is developing custom TALEN® for Cytovia to develop gene-edited iPSC-derived Natural Killer cellsCytovia and Isleworth Healthcare Acquisition Corp. announce business combination agreement and combined

Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma at the American Association for Cancer Research (AACR) 2022 Annual Meeting

News, Health Care, Press Releases

Preclinical data demonstrated POC with robust in vitro and in vivo anti-tumor activity UCART20x22 allogeneic dual CAR T has been designed and engineered on the TRAC / CD52 TALEN® platform UCART20x22 expected to be

Iovance Biotherapeutics' Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC)

Health Care, Press Releases

Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001 to Deliver TIL and PD-1 Inhibition within a Single Cancer Therapy First Genetically Modified Iovance TIL Therapy Leverages

Cellectis to Participate in Two Upcoming Investor Conferences in March

News, Press Releases

NEW YORK, March 11, 2022 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,

Thinking about buying stock in Excellon Resources, Cellectis, Superior Drilling Products, Safe T Group, or Drive Shack?

Opinion, Press Releases

NEW YORK, March 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EXN, CLLS, SDPI, SFET, and DS.

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results

Earnings, Press Releases

Encouraging preliminary results from BALLI-01 study (evaluating UCART22) in relapsed/refractory B-cell Acute Lymphoblastic Leukemia presented at ASH 2021 annual meeting; BALLI-01 currently enrolling at DL3 On track